Table 2.

Family #2 CYP26 and NAT2 Polymorphism Phenotypes

ID#	Gender	Cancer	Age of dx	Smoker	CYP26 (Debrisoquine metabolism)	NAT2 (Caffeine metabolism)
III-1	M	Bladder	45	Y	MR=1.64 (intermediate)	MR=0.63 (rapid)
III-2	M	Bladder	47	Y	MR=1.0 (intermediate)	MR=0.40 (rapid)
III-3	F	N		N	MR=1.38 (intermediate)	MR=1.45 (rapid)
IV-1	M	N		N	MR=1.11 (intermediate)	MR=0.08 (rapid)
IV-2	F	N		N	MR=1.29 (intermediate)	N/D
IV-3	M	N		N	MR=0.84 (extensive)	MR=0.31 (rapid)
IV-4	F	N		N	MR=0.48 (extensive)	N/D
IV-5	F	N		N	MR=69.6 (poor)	MR=0.56 (rapid)

^*MR = Metabolic ratio of debrisoquine to 2-hydroxy-debrisoquine. The following values are used to assign the genotype based on the MR: Extensive metabolizer = 0–1, homozygous dominant genotype; intermediate metabolizer=1–12, heterozygous genotype; and deficient (poor) metabolizer >12, homozygous recessive genotype.

^**MR = Molar ratio of 5-acetylamino-6-formylamino-3methyluracil (AFMU) to 1-methylxanthine (1X)

N/D = sample inadequate